Keywords: ladribine, Movectro, Merck Serono, Merck KGaA, Australia, Multiple sclerosis
Merck Serono's oral MS drug cladribine gets second approval, in Australia
Article | 06 September 2010
The Australian Therapeutic Goods Administration (TGA) has approved German drug major Merck KGaA (FWB: MRK) subsidiary Merck Serono’s cladribine ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
